alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis: Cochrane systematic review

alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis: Cochrane systematic review is a topic covered in the Cochrane Abstracts.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis: Cochrane systematic review ID - 438530 PB - Cochrane Abstracts UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438530/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing_remitting_multiple_sclerosis:_Cochrane_systematic_review ER -